Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - K-V Pharmaceutical Co | d8k.htm |
| EX-99.1 - CONSOLIDATED FINANCIAL STATEMENTS AND NOTES - K-V Pharmaceutical Co | dex991.htm |
| EX-23.2 - CONSENT OF KPMG LLP - K-V Pharmaceutical Co | dex232.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Board of Directors and Shareholders
K-V Pharmaceutical Company
Bridgeton, Missouri
We hereby consent to the incorporation by reference in the Registration Statements (Nos. 33-44927, 333-00199, 333-48252 and 333-85516) on Form S-8 and the Registration Statements (Nos. 333-87402 and 333-106294) on Form S-3 of K-V Pharmaceutical Company (the Company) of our report dated June 10, 2011 (except for the 2011 and 2010 condensed consolidating financial information as presented in Note 26, which is as of July 8, 2011) relating to the consolidated financial statements and financial statement schedule, and of our report dated June 10, 2011 related to the effectiveness of the Company’s internal control over financial reporting which appear in this Form 10-K.
Our report on the consolidated financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
Our report on the effectiveness of internal control over financial reporting expresses an adverse opinion on the effectiveness of the Company’s internal control over financial reporting as of March 31, 2011.
| /s/ BDO USA, LLP |
| Chicago, Illinois |
| July 8, 2011 |